PanTheryx Clinical Trials

The proven power of nutritional interventions to address serious diseases.

PanTheryx has reimagined the approach to addressing serious GI-related health conditions by focusing on researching and developing naturally derived, broad-based solutions that are efficacious, cost-effective, and safe—even for children, the elderly, and other vulnerable populations.

Our Guatemala Clinical Trial

Resolution of Symptoms

Our research and experience with colostrum, eggs, and other nutrients demonstrate the potential that we can develop nutrition-based compounds that repair the gut, reduce inflammation, reset the microbiome, and target the underlying causes of a wide range of serious GI and other health conditions.

Our lead medical nutrition products are specially formulated to address the specific dietary needs of children with infectious diarrhea, resulting from a variety of sources. The nutritional deficiencies and malnutrition resulting from diarrhea have been extensively researched, are well-established and understood by the medical community. PanTheryx products have been shown in open-label and double blind placebo clinical trials to be effective in addressing the nutrient needs of children with infectious diarrhea, which results in the restoration of intestinal health and function.

PanTheryx Clinical Trials

The proven power of nutritional interventions to address serious diseases.

PanTheryx has reimagined the approach to addressing serious GI-related health conditions by focusing on researching and developing naturally derived, broad-based solutions that are simple, cost-effective, and safe—even for children, the elderly, and other vulnerable populations.

Our Guatemala Clinical Trial

Resolution of Symptoms

Our research and experience with colostrum, eggs, and other nutrients demonstrate the potential that we can develop nutrition-based compounds that repair the gut, reduce inflammation, reset the microbiome, and target the underlying causes of a wide range of serious GI and other health conditions.

Our lead medical nutrition products are specially formulated to address the specific dietary needs of children with infectious diarrhea, resulting from a variety of sources. The nutritional deficiencies and malnutrition resulting from diarrhea have been extensively researched, are well-established and understood by the medical community. PanTheryx products have been shown in open-label and double blind placebo clinical trials to be effective in addressing the nutrient needs of children with infectious diarrhea, which results in the restoration of intestinal health and function.

Shown to Be Safe and Effective

In recent studies our products have been shown to effectively treat infectious diarrhea in Guatemala. We have confirmed the efficacy of our products in non-differentiated diarrhea in open label clinical trials and, with statistical significance against key targeted pathogens in a double-blind, placebo controlled clinical trial. Safety has been confirmed by both open label and double-blind, placebo controlled trials.

Efficacy of a Novel Nutritional Product in Acute Childhood Diarrhea in Guatemala:

Secondary and Exploratory Analyses of a Randomized, Double Blind, Placebo Controlled Trial.

Day 1
p-value: .021
Day 2
p-value: .045
Day 3
p-value: .026
Day 7
p-value: .092
Day 1
p-value: .021
Day 2
p-value: .045
Day 3
p-value: .026
Day 7
p-value: .092

Our team is dedicated to investing in research that will further validate our patented technology platform, and generate scientific evidence to support the potential of nutritional ingredients like colostrum, to influence a broad range of diseases and conditions. To date we have four peer reviewed scientific publications from our clinical trials:

Kamidani S et al. Serial Multiplex PCR May Help Differentiate Causal Pathogens from Colonizing Organisms in Children with Acute Diarrhea in Guatemala. Abstract, IDSA, 2017.
Download
Gaensbauer J et al. Efficacy of a Novel Nutritional Product in Acute Childhood Diarrhea in Guatemala: Secondary and Exploratory Analyses of a Randomized, Double Blind, Placebo Controlled Trial. Abstract, IDSA, 2017.
Download
Lamb M et al. Nutritional Status is Not Associated with Diarrhea Duration or Weight Recovery in Young Children in a Resource-Poor Setting. Abstract, IDSA, 2017.
Download
Melgar M. Enteropathogen Identification by Multiplex PCR in Guatemalan Children with Acute, Nonbloody Diarrhea. Abstract, IDSA, 2017.
Download

Our studies are helping to drive the body of knowledge around the impact of the microbiome on health, especially in children, the elderly, and other vulnerable populations.

We take a strategic, evidence-based approach to all we do.

PanTheryx is committed to continuing to build our IP, extend our patented technology platform, and generate scientific evidence to support our unique, broad-spectrum, nutrition-based solutions to repair the gut, reduce inflammation, reset the microbiome, and address the underlying issues of complex health challenges.

PanTheryx is able to leverage what we’ve learned from clinical research as well as the real-world use of our products, even under the most difficult of conditions, to better identify the potential of our platform technology to address other serious GI conditions.

Continued Research

Current research efforts are exploring the potential of our nutrition-based solutions to address the issue of stunting in malnourished children across the globe.

Our research pipeline targets serious GI-related conditions—such as C. difficile infection (CDI), IBS/IBD, leaky gut, and infectious diarrhea— where our patented platform is most likely to lead to viable therapeutics that are safe and effective in children, adults, and vulnerable populations.